Results 191 to 200 of about 949,142 (303)

Establishment of Humanized EFNB2/B3 Murine Models for Investigating Nipah Virus Pathogenesis

Animal Research and One Health, EarlyView.
ABSTRACT Nipah virus (NiV) is a zoonotic paramyxovirus classified as a WHO priority pathogen, which causes severe respiratory disease and encephalitis in humans with high mortality. Currently, no licensed vaccines or specific antiviral therapies are available.
Wei Dong, Ning Liu, Weining Kong, Xiang Gao, Feifei Guan, Shan Gao, Yuanwu Ma   +6 more
wiley   +1 more source

Arming Inactivated Enveloped Virus Vaccines with the <i>GGTA1</i> Gene: A Potent Method for Amplification of Viral Vaccines Effectiveness and Protection Against Variants. [PDF]

Vaccines (Basel)
Galili U.
europepmc   +1 more source

Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing

Animal Research and One Health, EarlyView.
Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley   +1 more source

Viral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions. [PDF]

Pathogens
Li D, Zhang X, Apley MD, Gebhardt JT, Karriker L, Connor JF, Bromfield C, Lubbers B, Kittana H, Pendell D, Madera R, Muro N, Craig A, Shenkenberg B, Li Y, Wang L, Shi J.   +16 more
europepmc   +1 more source

Early type I IFN blockade improves the efficacy of viral vaccines. [PDF]

J Exp Med, 2020
Palacio N, Dangi T, Chung YR, Wang Y, Loredo-Varela JL, Zhang Z, Penaloza-MacMaster P.   +6 more
europepmc   +1 more source

Differences in SARS‐CoV‐2 Antigen Persistence in Individuals With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post–acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M. M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, on behalf of RECOVER‐Adult   +18 more
wiley   +1 more source

Artificial Intelligence Driven Framework for the Design and Development of Next-Generation Avian Viral Vaccines. [PDF]

Microorganisms
Goud MD, Ramos E, Shah AU, Hemida MG.
europepmc   +1 more source

Overview of COVID-19 vaccines [PDF]

Updated Aug. 23, 2022There are four approved or authorized vaccines in the United States used to prevent COVID-19. Pfizer-BioNTech and Moderna are COVID-19 mRNA vaccines. You can also get the Novavax COVID-19 protein subunit vaccine.

core  

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Bibliometric analysis of global research output on viral vaccines and antivirals in the 21st century. [PDF]

Virol Sin
Ma L, Pan W, Yan M, Si J.
europepmc   +1 more source